Glucose and lipopolysaccharide differentially regulate fibroblast growth factor 21 in healthy male human volunteers – A prospective cross‐over trial

Fibroblast growth factor 21 (FGF21) affects the regulation of metabolism. Additionally, anti‐inflammatory properties are attributed to FGF21, and studies in animals and humans show conflicting results. This study aimed to investigate how FGF21 is affected by glucose and lipopolysaccharide (LPS) in h...

Full description

Saved in:
Bibliographic Details
Published inJournal of cellular and molecular medicine Vol. 26; no. 24; pp. 5998 - 6005
Main Authors Pohlhammer, Johannes, Heinzl, Matthias Wolfgang, Klammer, Carmen, Feldbauer, Roland, Rosenberger, Klemens, Resl, Michael, Wagner, Thomas, Obendorf, Florian, Egger‐Salmhofer, Margot, Dieplinger, Benjamin, Clodi, Martin
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.12.2022
John Wiley and Sons Inc
Subjects
Adenosine
Apoptosis
Blood pressure
Body fat
Creatinine
Cross-Over Studies
Cytokines
Deoxyribonucleic acid
DNA
Electrocardiography
fibroblast growth factor 21
Fibroblast growth factors
Fibroblast Growth Factors - metabolism
Fibroblasts
Glucose
Growth factors
Healthy Volunteers
human endotoxin model
Humans
Hyperglycemia
Inflammation
lipopolysaccharide
Lipopolysaccharides
Lipopolysaccharides - pharmacology
Liver
Male
Metabolism
Original
Oxidative stress
Peptides
Prospective Studies
Protein expression
Proteins
Statistical analysis
Variance analysis
fibroblast growth factor 21
lipopolysaccharide
human endotoxin model
Online AccessGet full text
ISSN1582-1838
1582-4934
1582-4934
DOI10.1111/jcmm.17614

Cover

Abstract Fibroblast growth factor 21 (FGF21) affects the regulation of metabolism. Additionally, anti‐inflammatory properties are attributed to FGF21, and studies in animals and humans show conflicting results. This study aimed to investigate how FGF21 is affected by glucose and lipopolysaccharide (LPS) in humans. Therefore, FGF21 was measured eight times at different time points within 48 h in this prospective cross‐over trial after glucose and LPS on two different study days. The study included ten healthy, non‐smoking male subjects aged 18–40. Repeated measures analysis of variance and paired t‐test as post hoc analysis were applied. The administration of glucose and LPS resulted in a significant difference in regulating FGF21 (p < 0.001). After glucose administration, FGF21 declined sharply at 360 min, with a subsequent steep increase that exceeded baseline levels. LPS induced a drop in FGF21 after 180 min, while the baseline concentrations were not reached. After 180 min and 24 h, a statistically significant difference was demonstrated after adjusting the Bonferroni–Holm method. So, our results support the hypothesis that glucose and LPS differentially affect the human expression of FGF21 over 48 h.
AbstractList Fibroblast growth factor 21 (FGF21) affects the regulation of metabolism. Additionally, anti-inflammatory properties are attributed to FGF21, and studies in animals and humans show conflicting results. This study aimed to investigate how FGF21 is affected by glucose and lipopolysaccharide (LPS) in humans. Therefore, FGF21 was measured eight times at different time points within 48 h in this prospective cross-over trial after glucose and LPS on two different study days. The study included ten healthy, non-smoking male subjects aged 18-40. Repeated measures analysis of variance and paired t-test as post hoc analysis were applied. The administration of glucose and LPS resulted in a significant difference in regulating FGF21 (p < 0.001). After glucose administration, FGF21 declined sharply at 360 min, with a subsequent steep increase that exceeded baseline levels. LPS induced a drop in FGF21 after 180 min, while the baseline concentrations were not reached. After 180 min and 24 h, a statistically significant difference was demonstrated after adjusting the Bonferroni-Holm method. So, our results support the hypothesis that glucose and LPS differentially affect the human expression of FGF21 over 48 h.Fibroblast growth factor 21 (FGF21) affects the regulation of metabolism. Additionally, anti-inflammatory properties are attributed to FGF21, and studies in animals and humans show conflicting results. This study aimed to investigate how FGF21 is affected by glucose and lipopolysaccharide (LPS) in humans. Therefore, FGF21 was measured eight times at different time points within 48 h in this prospective cross-over trial after glucose and LPS on two different study days. The study included ten healthy, non-smoking male subjects aged 18-40. Repeated measures analysis of variance and paired t-test as post hoc analysis were applied. The administration of glucose and LPS resulted in a significant difference in regulating FGF21 (p < 0.001). After glucose administration, FGF21 declined sharply at 360 min, with a subsequent steep increase that exceeded baseline levels. LPS induced a drop in FGF21 after 180 min, while the baseline concentrations were not reached. After 180 min and 24 h, a statistically significant difference was demonstrated after adjusting the Bonferroni-Holm method. So, our results support the hypothesis that glucose and LPS differentially affect the human expression of FGF21 over 48 h.
Fibroblast growth factor 21 (FGF21) affects the regulation of metabolism. Additionally, anti-inflammatory properties are attributed to FGF21, and studies in animals and humans show conflicting results. This study aimed to investigate how FGF21 is affected by glucose and lipopolysaccharide (LPS) in humans. Therefore, FGF21 was measured eight times at different time points within 48 h in this prospective cross-over trial after glucose and LPS on two different study days. The study included ten healthy, non-smoking male subjects aged 18-40. Repeated measures analysis of variance and paired t-test as post hoc analysis were applied. The administration of glucose and LPS resulted in a significant difference in regulating FGF21 (p < 0.001). After glucose administration, FGF21 declined sharply at 360 min, with a subsequent steep increase that exceeded baseline levels. LPS induced a drop in FGF21 after 180 min, while the baseline concentrations were not reached. After 180 min and 24 h, a statistically significant difference was demonstrated after adjusting the Bonferroni-Holm method. So, our results support the hypothesis that glucose and LPS differentially affect the human expression of FGF21 over 48 h.
Fibroblast growth factor 21 (FGF21) affects the regulation of metabolism. Additionally, anti‐inflammatory properties are attributed to FGF21, and studies in animals and humans show conflicting results. This study aimed to investigate how FGF21 is affected by glucose and lipopolysaccharide (LPS) in humans. Therefore, FGF21 was measured eight times at different time points within 48 h in this prospective cross‐over trial after glucose and LPS on two different study days. The study included ten healthy, non‐smoking male subjects aged 18–40. Repeated measures analysis of variance and paired t‐test as post hoc analysis were applied. The administration of glucose and LPS resulted in a significant difference in regulating FGF21 (p < 0.001). After glucose administration, FGF21 declined sharply at 360 min, with a subsequent steep increase that exceeded baseline levels. LPS induced a drop in FGF21 after 180 min, while the baseline concentrations were not reached. After 180 min and 24 h, a statistically significant difference was demonstrated after adjusting the Bonferroni–Holm method. So, our results support the hypothesis that glucose and LPS differentially affect the human expression of FGF21 over 48 h.
Fibroblast growth factor 21 (FGF21) affects the regulation of metabolism. Additionally, anti‐inflammatory properties are attributed to FGF21, and studies in animals and humans show conflicting results. This study aimed to investigate how FGF21 is affected by glucose and lipopolysaccharide (LPS) in humans. Therefore, FGF21 was measured eight times at different time points within 48 h in this prospective cross‐over trial after glucose and LPS on two different study days. The study included ten healthy, non‐smoking male subjects aged 18–40. Repeated measures analysis of variance and paired t ‐test as post hoc analysis were applied. The administration of glucose and LPS resulted in a significant difference in regulating FGF21 ( p  < 0.001). After glucose administration, FGF21 declined sharply at 360 min, with a subsequent steep increase that exceeded baseline levels. LPS induced a drop in FGF21 after 180 min, while the baseline concentrations were not reached. After 180 min and 24 h, a statistically significant difference was demonstrated after adjusting the Bonferroni–Holm method. So, our results support the hypothesis that glucose and LPS differentially affect the human expression of FGF21 over 48 h.
Author Wagner, Thomas
Heinzl, Matthias Wolfgang
Klammer, Carmen
Feldbauer, Roland
Rosenberger, Klemens
Dieplinger, Benjamin
Obendorf, Florian
Resl, Michael
Egger‐Salmhofer, Margot
Pohlhammer, Johannes
Clodi, Martin
AuthorAffiliation 1 Department of Medicine Konventhospital Barmherzige Brueder Linz (St. John of God Hospital Linz) Linz Austria
3 Department of Internal Medicine Klinikum Rohrbach Rohrbach Austria
2 ICMR–Institute for Cardiovascular and Metabolic Research, JKU Linz Linz Austria
4 Department of Laboratory Medicine Konventhospital Barmherzige Brueder Linz and Ordensklinikum Linz Barmherzige Schwestern Linz Austria
AuthorAffiliation_xml – name: 3 Department of Internal Medicine Klinikum Rohrbach Rohrbach Austria
– name: 4 Department of Laboratory Medicine Konventhospital Barmherzige Brueder Linz and Ordensklinikum Linz Barmherzige Schwestern Linz Austria
– name: 1 Department of Medicine Konventhospital Barmherzige Brueder Linz (St. John of God Hospital Linz) Linz Austria
– name: 2 ICMR–Institute for Cardiovascular and Metabolic Research, JKU Linz Linz Austria
Author_xml – sequence: 1
  givenname: Johannes
  orcidid: 0000-0001-7477-9019
  surname: Pohlhammer
  fullname: Pohlhammer, Johannes
  organization: ICMR–Institute for Cardiovascular and Metabolic Research, JKU Linz
– sequence: 2
  givenname: Matthias Wolfgang
  surname: Heinzl
  fullname: Heinzl, Matthias Wolfgang
  organization: ICMR–Institute for Cardiovascular and Metabolic Research, JKU Linz
– sequence: 3
  givenname: Carmen
  surname: Klammer
  fullname: Klammer, Carmen
  organization: ICMR–Institute for Cardiovascular and Metabolic Research, JKU Linz
– sequence: 4
  givenname: Roland
  surname: Feldbauer
  fullname: Feldbauer, Roland
  organization: ICMR–Institute for Cardiovascular and Metabolic Research, JKU Linz
– sequence: 5
  givenname: Klemens
  surname: Rosenberger
  fullname: Rosenberger, Klemens
  organization: Klinikum Rohrbach
– sequence: 6
  givenname: Michael
  surname: Resl
  fullname: Resl, Michael
  organization: ICMR–Institute for Cardiovascular and Metabolic Research, JKU Linz
– sequence: 7
  givenname: Thomas
  surname: Wagner
  fullname: Wagner, Thomas
  organization: ICMR–Institute for Cardiovascular and Metabolic Research, JKU Linz
– sequence: 8
  givenname: Florian
  surname: Obendorf
  fullname: Obendorf, Florian
  organization: ICMR–Institute for Cardiovascular and Metabolic Research, JKU Linz
– sequence: 9
  givenname: Margot
  surname: Egger‐Salmhofer
  fullname: Egger‐Salmhofer, Margot
  organization: Konventhospital Barmherzige Brueder Linz and Ordensklinikum Linz Barmherzige Schwestern
– sequence: 10
  givenname: Benjamin
  surname: Dieplinger
  fullname: Dieplinger, Benjamin
  organization: Konventhospital Barmherzige Brueder Linz and Ordensklinikum Linz Barmherzige Schwestern
– sequence: 11
  givenname: Martin
  surname: Clodi
  fullname: Clodi, Martin
  email: martin.clodi@bblinz.at
  organization: ICMR–Institute for Cardiovascular and Metabolic Research, JKU Linz
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36415151$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAQgCNURH_gwgMgS1wQaEscO38XpGoFBdSKC5ytsTPZ9cqJg-3sKrc-AhInbjwLj9Inwdtd_ipU--CR_M145vNxctDbHpPkMU1PaVwvV6rrTmlZUH4vOaJ5lc14zfjBPqYVqw6TY-9XacoKyuoHySErOM3jPkq-nZtRWY8E-oYYPdjBmsmDUktwukHS6LZFh33QYMxEHC5GAwFJq6Wz0oAPZOHsJixJCypYRzJKdE-WCCYsJ9KBQbIcO-jJ2pqxD4jOk-urr-Tsx_fBWT-gCnqNRMXYX199sWt0JLj42sPkfgvG46P9eZJ8evP64_zt7OLD-bv52cVMcV7xGeaFhFpWKcqyLFLOWQEqHjKrOKuxoKVsoMkAC9Uy2WRllnEqc5BSQk6xYSfJi13dsR9g2sQxxeB0B24SNBVbwWIrWNwIjvSrHT2MssNGRTMO_mRY0OLfm14vxcKuRV3mjLMyFni2L-Ds5xF9EJ32Co2BHu3oRVaymjPKqi369Ba6sqPro4xI5XHSuk6LSD35u6Pfrfz64wikO-DGscNWKB0gaLttUJv_T_n8VsqdSugO3miD0x2keD-_vNzl_ARO3d7H
CitedBy_id crossref_primary_10_4103_mj_mj_38_24
Cites_doi 10.1016/j.cmet.2015.12.003
10.1080/10520295.2021.1894353
10.2337/dc09-0684
10.1038/ijo.2014.76
10.1038/s42255-021-00354-2
10.1007/s10741-019-09809-x
10.1093/abbs/gmu097
10.1016/j.cmet.2015.12.008
10.1007/s11845-017-1554-7
10.1016/j.molmet.2014.09.008
10.1007/s12265-021-10109-9
10.1016/j.febslet.2008.04.038
10.1016/j.febslet.2009.07.053
10.1146/annurev-physiol-021115-105339
10.1371/journal.pone.0164351
10.1016/j.molmet.2016.11.008
10.4110/in.2013.13.4.123
10.1139/cjpp-2014-0227
10.1530/EC-13-0040
10.1038/s41598-020-76593-2
10.2337/dc11-0294
10.1016/j.intimp.2021.107634
10.1007/s12020-014-0433-5
10.1016/j.intimp.2016.05.026
10.1111/j.1365-2265.2008.03502.x
10.1128/IAI.00842-19
10.2174/092986708784872393
10.1016/j.cyto.2018.05.020
10.1101/gad.344556.120
10.1016/j.tem.2019.05.007
10.1096/fj.00-0829hyp
10.1210/jc.2012-1132
10.1016/j.molmet.2016.11.001
10.1371/journal.pone.0094996
10.1210/en.2003-1671
10.1038/clpt.2014.146
10.1073/pnas.0701600104
10.2174/1871530315666150316124019
10.1161/CIRCULATIONAHA.115.015308
10.1210/endo.143.5.8850
10.1074/jbc.M116.715151
10.1371/journal.pone.0148252
10.1016/j.febslet.2008.11.023
10.1210/en.2009-0221
10.1093/cvr/cvu263
10.1111/j.1747-0285.2012.01325.x
10.1016/j.molmet.2017.03.009
10.2337/db10-0193
10.2337/db19-235-LB
10.1016/j.celrep.2017.09.065
10.33549/physiolres.932099
10.1016/j.bbrc.2012.07.165
10.1183/13993003.00973-2018
10.1210/en.2011-1496
10.1016/j.cmet.2017.03.005
10.1530/EC-16-0103
ContentType Journal Article
Copyright 2022 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2022 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
– notice: 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
– notice: 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QP
7TK
7X7
7XB
88E
88I
8AO
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
RC3
7X8
5PM
ADTOC
UNPAY
DOI 10.1111/jcmm.17614
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Database
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
Medical Database
Science Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Publicly Available Content Database
CrossRef
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate Pohlhammer et al
EISSN 1582-4934
EndPage 6005
ExternalDocumentID 10.1111/jcmm.17614
PMC9753437
36415151
10_1111_jcmm_17614
JCMM17614
Genre article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: NIH Clinical Center
– fundername: Oesterreichische Nationalbank
  funderid: Anniversary Fund, project number 16415
– fundername: ;
– fundername: ;
  grantid: Anniversary Fund, project number 16415
GroupedDBID ---
0R~
1OC
24P
29K
31~
36B
3V.
4.4
53G
5GY
5VS
7X7
8-0
8-1
88E
88I
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
AAHHS
AAZKR
ABUWG
ACCFJ
ACCMX
ACGFS
ACGOD
ACXQS
ADBBV
ADKYN
ADPDF
ADRAZ
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFBPY
AFKRA
AFZJQ
AHMBA
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
D-9
D-I
DIK
DU5
DWQXO
E3Z
EBD
EBS
EJD
EMB
EMOBN
F5P
FYUFA
GNUQQ
GODZA
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IHR
ITC
KQ8
LH4
LK8
LW6
M1P
M2P
M48
M7P
O9-
OIG
OK1
OVD
OVEED
PIMPY
PQQKQ
PROAC
PSQYO
Q2X
RNS
ROL
RPM
SV3
TEORI
UKHRP
WIN
AAMMB
AAYXX
ABJNI
AEFGJ
AGXDD
AIDQK
AIDYY
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PUEGO
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TK
7XB
8FD
8FK
FR3
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
Q9U
RC3
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c4484-e56ba9b80eb77604436ac044b28439e617bdad2ae6cf3bd272241b5abbba51ed3
IEDL.DBID BENPR
ISSN 1582-1838
1582-4934
IngestDate Sun Oct 26 04:02:02 EDT 2025
Tue Sep 30 17:17:44 EDT 2025
Thu Sep 04 18:14:05 EDT 2025
Tue Oct 07 06:57:20 EDT 2025
Mon Jul 21 05:36:52 EDT 2025
Thu Apr 24 22:51:35 EDT 2025
Wed Oct 01 06:33:49 EDT 2025
Wed Jan 22 16:25:58 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 24
Keywords fibroblast growth factor 21
lipopolysaccharide
human endotoxin model
Language English
License Attribution
2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4484-e56ba9b80eb77604436ac044b28439e617bdad2ae6cf3bd272241b5abbba51ed3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0001-7477-9019
OpenAccessLink https://www.proquest.com/docview/2754439906?pq-origsite=%requestingapplication%&accountid=15518
PMID 36415151
PQID 2754439906
PQPubID 2034150
PageCount 8
ParticipantIDs unpaywall_primary_10_1111_jcmm_17614
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9753437
proquest_miscellaneous_2739431387
proquest_journals_2754439906
pubmed_primary_36415151
crossref_citationtrail_10_1111_jcmm_17614
crossref_primary_10_1111_jcmm_17614
wiley_primary_10_1111_jcmm_17614_JCMM17614
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate December 2022
PublicationDateYYYYMMDD 2022-12-01
PublicationDate_xml – month: 12
  year: 2022
  text: December 2022
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Chichester
– name: Hoboken
PublicationTitle Journal of cellular and molecular medicine
PublicationTitleAlternate J Cell Mol Med
PublicationYear 2022
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
References 2017; 6
2007; 104
2015; 39
2010; 59
2013; 2
2019; 53
2011; 60
2016; 30
2009; 150
2015; 106
2020; 10
2016; 38
2008; 582
2012; 97
2016; 78
2021; 35
2015; 49
2002; 143
2013; 13
2019; 24
2019; 68
2015; 131
2001; 15
2020; 88
2014; 9
2014; 96
2004; 145
2015; 15
2014; 92
2021; 3
2019; 6
2015; 4
2019; 30
2017; 25
2017; 21
2008; 15
2014; 46
2011; 34
2012; 79
2021; 96
2012; 425
2016; 11
2021; 14
2018; 111
2012; 153
2009; 32
2009; 71
2009; 583
2022; 97
2017; 186
2016; 291
2018; 10
2016; 23
e_1_2_10_23_1
e_1_2_10_46_1
e_1_2_10_21_1
Refsgaard Holm M (e_1_2_10_31_1) 2019; 6
e_1_2_10_44_1
e_1_2_10_42_1
e_1_2_10_40_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_53_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_39_1
e_1_2_10_55_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_37_1
e_1_2_10_57_1
e_1_2_10_58_1
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_11_1
e_1_2_10_32_1
e_1_2_10_30_1
e_1_2_10_51_1
e_1_2_10_29_1
e_1_2_10_25_1
e_1_2_10_48_1
Chen H (e_1_2_10_27_1) 2018; 10
e_1_2_10_24_1
e_1_2_10_45_1
e_1_2_10_22_1
e_1_2_10_43_1
e_1_2_10_20_1
e_1_2_10_41_1
e_1_2_10_52_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_54_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_38_1
e_1_2_10_56_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_36_1
e_1_2_10_12_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_59_1
e_1_2_10_10_1
e_1_2_10_33_1
Erickson A (e_1_2_10_2_1) 2016; 30
e_1_2_10_50_1
e_1_2_10_60_1
e_1_2_10_28_1
e_1_2_10_49_1
e_1_2_10_26_1
e_1_2_10_47_1
References_xml – volume: 30
  year: 2016
  article-title: The regulation of FGF21 gene expression by metabolic factors and nutrients
  publication-title: Horm Mol Biol Clin Investig
– volume: 34
  start-page: 2113
  year: 2011
  end-page: 2115
  article-title: High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4‐year population‐based prospective study in Chinese subjects
  publication-title: Diabetes Care
– volume: 6
  start-page: 22
  year: 2017
  end-page: 29
  article-title: Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates
  publication-title: Mol Metab
– volume: 92
  start-page: 927
  year: 2014
  end-page: 935
  article-title: Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo
  publication-title: Can J Physiol Pharmacol
– volume: 153
  start-page: 2689
  year: 2012
  end-page: 2700
  article-title: FGF21 is increased by inflammatory stimuli and protects leptin‐deficient Ob/Ob mice from the toxicity of sepsis
  publication-title: Endocrinology
– volume: 582
  start-page: 1725
  year: 2008
  end-page: 1730
  article-title: FGF21 attenuates lipolysis in human adipocytes ‐ a possible link to improved insulin sensitivity
  publication-title: FEBS Lett
– volume: 583
  start-page: 19
  year: 2009
  end-page: 24
  article-title: FGF21 N‐ and C‐termini play different roles in receptor interaction and activation
  publication-title: FEBS Lett
– volume: 291
  start-page: 15378
  year: 2016
  end-page: 15387
  article-title: Hepatic aryl hydrocarbon receptor attenuates fibroblast growth factor 21 expression
  publication-title: J Biol Chem
– volume: 78
  start-page: 223
  year: 2016
  end-page: 241
  article-title: Understanding the physiology of FGF21
  publication-title: Annu Rev Physiol
– volume: 186
  start-page: 785
  year: 2017
  end-page: 794
  article-title: Circulating levels of fibroblast growth factor 21 in early‐stage diabetic kidney disease
  publication-title: Ir J Med Sci
– volume: 6
  start-page: 602
  year: 2017
  end-page: 610
  article-title: FGF21 resistance is not mediated by downregulation of beta‐klotho expression in white adipose tissue
  publication-title: Mol Metab
– volume: 10
  start-page: 19521
  year: 2020
  article-title: FGF21 signaling in glutamatergic neurons is required for weight loss associated with dietary protein dilution
  publication-title: Sci Rep
– volume: 9
  year: 2014
  article-title: Glucagon stimulates hepatic FGF21 secretion through a PKA‐ and EPAC‐dependent posttranscriptional mechanism
  publication-title: PLoS One
– volume: 106
  start-page: 19
  year: 2015
  end-page: 31
  article-title: Fibroblast growth factor 21 protects the heart from oxidative stress
  publication-title: Cardiovasc Res
– volume: 13
  start-page: 123
  year: 2013
  end-page: 132
  article-title: Metformin Down‐regulates TNF‐alpha secretion via suppression of scavenger receptors in macrophages
  publication-title: Immune Netw
– volume: 11
  year: 2016
  article-title: Fibroblast growth factor 21 (FGF21) protects against high fat diet induced inflammation and islet hyperplasia in pancreas
  publication-title: PLoS One
– volume: 32
  start-page: 1542
  year: 2009
  end-page: 1546
  article-title: Circulating fibroblast growth factor‐21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance
  publication-title: Diabetes Care
– volume: 97
  start-page: E1224
  year: 2012
  end-page: E1228
  article-title: Dynamic change of serum FGF21 levels in response to glucose challenge in human
  publication-title: J Clin Endocrinol Metab
– volume: 49
  start-page: 119
  year: 2015
  end-page: 129
  article-title: Recombinant murine fibroblast growth factor 21 ameliorates obesity‐related inflammation in monosodium glutamate‐induced obesity rats
  publication-title: Endocrine
– volume: 96
  start-page: 418
  year: 2014
  end-page: 422
  article-title: Human endotoxin administration as an experimental model in drug development
  publication-title: Clin Pharmacol Ther
– volume: 6
  start-page: 983
  year: 2019
  end-page: 991
  article-title: 'Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation',
  publication-title: Heart Fail
– volume: 71
  start-page: 369
  year: 2009
  end-page: 375
  article-title: Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor‐21 in patients with type 2 diabetes and obesity
  publication-title: Clin Endocrinol (Oxf)
– volume: 111
  start-page: 428
  year: 2018
  end-page: 433
  article-title: Early increases in serum FGF21 levels predict mortality of septic patients
  publication-title: Cytokine
– volume: 38
  start-page: 144
  year: 2016
  end-page: 152
  article-title: Fibroblast growth factor 21 (FGF21) inhibits macrophage‐mediated inflammation by activating Nrf2 and suppressing the NF‐kappaB signaling pathway
  publication-title: Int Immunopharmacol
– volume: 583
  start-page: 2882
  year: 2009
  end-page: 2886
  article-title: Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes
  publication-title: FEBS Lett
– volume: 10
  start-page: 2958
  year: 2018
  end-page: 2966
  article-title: A high circulating FGF21 level as a prognostic marker in patients with acute myocardial infarction
  publication-title: Am J Transl Res
– volume: 15
  start-page: 1697
  year: 2008
  end-page: 1705
  article-title: Human endotoxemia as a model of systemic inflammation
  publication-title: Curr Med Chem
– volume: 97
  start-page: 44
  year: 2022
  end-page: 52
  article-title: Effects of metformin on lipopolysaccharide induced inflammation by activating fibroblast growth factor 21
  publication-title: Biotech Histochem
– volume: 14
  start-page: 941
  year: 2021
  end-page: 947
  article-title: Storm of cardiovascular markers after LPS Administration in Human Volunteers
  publication-title: J Cardiovasc Transl Res
– volume: 21
  start-page: 403
  year: 2017
  end-page: 416
  article-title: A specific ChREBP and PPARalpha cross‐talk is required for the glucose‐mediated FGF21 response
  publication-title: Cell Rep
– volume: 46
  start-page: 1041
  year: 2014
  end-page: 1048
  article-title: FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK‐SIRT1 pathway
  publication-title: Acta Biochim Biophys Sin (Shanghai)
– volume: 79
  start-page: 398
  year: 2012
  end-page: 410
  article-title: Understanding the physical interactions in the FGF21/FGFR/beta‐klotho complex: structural requirements and implications in FGF21 signaling
  publication-title: Chem Biol Drug des
– volume: 59
  start-page: 2781
  year: 2010
  end-page: 2789
  article-title: Obesity is a fibroblast growth factor 21 (FGF21)‐resistant state
  publication-title: Diabetes
– volume: 88
  year: 2020
  article-title: Proprotein convertase Subtilisin/Kexin type 9 (PCSK9) is not induced in artificial human inflammation and is not correlated with inflammatory response
  publication-title: Infect Immun
– volume: 25
  start-page: 935
  year: 2017
  end-page: 944
  article-title: FGF21 regulates metabolism through adipose‐dependent and ‐independent mechanisms
  publication-title: Cell Metab
– volume: 4
  start-page: 51
  year: 2015
  end-page: 57
  article-title: Fructose ingestion acutely stimulates circulating FGF21 levels in humans
  publication-title: Mol Metab
– volume: 39
  start-page: 121
  year: 2015
  end-page: 129
  article-title: Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients
  publication-title: Int J Obes (Lond)
– volume: 23
  start-page: 344
  year: 2016
  end-page: 349
  article-title: FGF21 regulates sweet and alcohol preference
  publication-title: Cell Metab
– volume: 53
  start-page: 1800973
  year: 2019
  article-title: Fibroblast growth factor 21 predicts outcome in community‐acquired pneumonia: secondary analysis of two randomised controlled trials
  publication-title: Eur Respir J
– volume: 131
  start-page: 1861
  year: 2015
  end-page: 1871
  article-title: Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element‐binding protein‐2 and induction of adiponectin in mice
  publication-title: Circulation
– volume: 145
  start-page: 2594
  year: 2004
  end-page: 2603
  article-title: Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin‐deficient diabetes
  publication-title: Endocrinology
– volume: 143
  start-page: 1741
  year: 2002
  end-page: 1747
  article-title: Transgenic mice expressing human fibroblast growth factor‐19 display increased metabolic rate and decreased adiposity
  publication-title: Endocrinology
– volume: 2
  start-page: 146
  year: 2013
  end-page: 153
  article-title: Increased FGF21 plasma levels in humans with sepsis and SIRS
  publication-title: Endocr Connect
– volume: 6
  start-page: 14
  year: 2017
  end-page: 21
  article-title: A critical role for ChREBP‐mediated FGF21 secretion in hepatic fructose metabolism
  publication-title: Mol Metab
– volume: 24
  start-page: 1005
  year: 2019
  end-page: 1017
  article-title: A review of fibroblast growth factor 21 in diabetic cardiomyopathy
  publication-title: Heart Fail Rev
– volume: 150
  start-page: 4084
  year: 2009
  end-page: 4093
  article-title: Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity
  publication-title: Endocrinology
– volume: 30
  start-page: 491
  year: 2019
  end-page: 504
  article-title: Going Back to the biology of FGF21: new insights
  publication-title: Trends Endocrinol Metab
– volume: 425
  start-page: 866
  year: 2012
  end-page: 872
  article-title: Metformin inhibits inflammatory response via AMPK‐PTEN pathway in vascular smooth muscle cells
  publication-title: Biochem Biophys Res Commun
– volume: 3
  start-page: 309
  year: 2021
  end-page: 317
  article-title: Metabolic messengers: FGF21
  publication-title: Nat Metab
– volume: 11
  year: 2016
  article-title: Elevated serum fibroblast growth factor 21 in humans with acute pancreatitis
  publication-title: PLoS One
– volume: 15
  start-page: 1996
  year: 2001
  end-page: 2006
  article-title: Rationale for the existence of additional adipostatic hormones
  publication-title: FASEB J
– volume: 68
  start-page: 235
  year: 2019
  article-title: 'Erratum. serum fgf21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. diabetes 2008;57:1246–1253
  publication-title: Diabetes
– volume: 6
  start-page: 39
  year: 2017
  end-page: 43
  article-title: LPS infusion suppresses serum FGF21 levels in healthy adult volunteers
  publication-title: Endocr Connect
– volume: 104
  start-page: 7432
  year: 2007
  end-page: 7437
  article-title: BetaKlotho is required for metabolic activity of fibroblast growth factor 21
  publication-title: Proc Natl Acad Sci U S A
– volume: 35
  start-page: 133
  year: 2021
  end-page: 146
  article-title: A feed‐forward regulatory loop in adipose tissue promotes signaling by the hepatokine FGF21
  publication-title: Genes Dev
– volume: 96
  year: 2021
  article-title: FGF21 alleviates chronic inflammatory injury in the aging process through modulating polarization of macrophages
  publication-title: Int Immunopharmacol
– volume: 60
  start-page: 627
  year: 2011
  end-page: 636
  article-title: Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very‐low calorie diet and PPAR‐alpha agonist treatment
  publication-title: Physiol Res
– volume: 23
  start-page: 335
  year: 2016
  end-page: 343
  article-title: FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver
  publication-title: Cell Metab
– volume: 15
  start-page: 196
  year: 2015
  end-page: 205
  article-title: Metformin and inflammation: its potential beyond glucose‐lowering effect
  publication-title: Endocr Metab Immune Disord Drug Targets
– ident: e_1_2_10_5_1
  doi: 10.1016/j.cmet.2015.12.003
– ident: e_1_2_10_55_1
  doi: 10.1080/10520295.2021.1894353
– ident: e_1_2_10_41_1
  doi: 10.2337/dc09-0684
– ident: e_1_2_10_44_1
  doi: 10.1038/ijo.2014.76
– ident: e_1_2_10_16_1
  doi: 10.1038/s42255-021-00354-2
– ident: e_1_2_10_15_1
  doi: 10.1007/s10741-019-09809-x
– ident: e_1_2_10_24_1
  doi: 10.1093/abbs/gmu097
– ident: e_1_2_10_49_1
  doi: 10.1016/j.cmet.2015.12.008
– ident: e_1_2_10_22_1
  doi: 10.1007/s11845-017-1554-7
– ident: e_1_2_10_40_1
  doi: 10.1016/j.molmet.2014.09.008
– ident: e_1_2_10_60_1
  doi: 10.1007/s12265-021-10109-9
– ident: e_1_2_10_42_1
  doi: 10.1016/j.febslet.2008.04.038
– ident: e_1_2_10_6_1
  doi: 10.1016/j.febslet.2009.07.053
– ident: e_1_2_10_8_1
  doi: 10.1146/annurev-physiol-021115-105339
– ident: e_1_2_10_29_1
  doi: 10.1371/journal.pone.0164351
– ident: e_1_2_10_48_1
  doi: 10.1016/j.molmet.2016.11.008
– ident: e_1_2_10_58_1
  doi: 10.4110/in.2013.13.4.123
– ident: e_1_2_10_25_1
  doi: 10.1139/cjpp-2014-0227
– ident: e_1_2_10_30_1
  doi: 10.1530/EC-13-0040
– volume: 10
  start-page: 2958
  year: 2018
  ident: e_1_2_10_27_1
  article-title: A high circulating FGF21 level as a prognostic marker in patients with acute myocardial infarction
  publication-title: Am J Transl Res
– ident: e_1_2_10_50_1
  doi: 10.1038/s41598-020-76593-2
– ident: e_1_2_10_20_1
  doi: 10.2337/dc11-0294
– ident: e_1_2_10_59_1
  doi: 10.1016/j.intimp.2021.107634
– ident: e_1_2_10_53_1
  doi: 10.1007/s12020-014-0433-5
– ident: e_1_2_10_35_1
  doi: 10.1016/j.intimp.2016.05.026
– ident: e_1_2_10_21_1
  doi: 10.1111/j.1365-2265.2008.03502.x
– ident: e_1_2_10_38_1
  doi: 10.1128/IAI.00842-19
– ident: e_1_2_10_36_1
  doi: 10.2174/092986708784872393
– ident: e_1_2_10_28_1
  doi: 10.1016/j.cyto.2018.05.020
– ident: e_1_2_10_43_1
  doi: 10.1101/gad.344556.120
– volume: 30
  year: 2016
  ident: e_1_2_10_2_1
  article-title: The regulation of FGF21 gene expression by metabolic factors and nutrients
  publication-title: Horm Mol Biol Clin Investig
– ident: e_1_2_10_9_1
  doi: 10.1016/j.tem.2019.05.007
– ident: e_1_2_10_51_1
  doi: 10.1096/fj.00-0829hyp
– ident: e_1_2_10_39_1
  doi: 10.1210/jc.2012-1132
– ident: e_1_2_10_19_1
  doi: 10.1016/j.molmet.2016.11.001
– ident: e_1_2_10_4_1
  doi: 10.1371/journal.pone.0094996
– ident: e_1_2_10_45_1
  doi: 10.1210/en.2003-1671
– volume: 6
  start-page: 983
  year: 2019
  ident: e_1_2_10_31_1
  article-title: 'Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation', ESC
  publication-title: Heart Fail
– ident: e_1_2_10_37_1
  doi: 10.1038/clpt.2014.146
– ident: e_1_2_10_13_1
  doi: 10.1073/pnas.0701600104
– ident: e_1_2_10_56_1
  doi: 10.2174/1871530315666150316124019
– ident: e_1_2_10_11_1
  doi: 10.1161/CIRCULATIONAHA.115.015308
– ident: e_1_2_10_46_1
  doi: 10.1210/endo.143.5.8850
– ident: e_1_2_10_3_1
  doi: 10.1074/jbc.M116.715151
– ident: e_1_2_10_52_1
  doi: 10.1371/journal.pone.0148252
– ident: e_1_2_10_14_1
  doi: 10.1016/j.febslet.2008.11.023
– ident: e_1_2_10_18_1
  doi: 10.1210/en.2009-0221
– ident: e_1_2_10_34_1
  doi: 10.1093/cvr/cvu263
– ident: e_1_2_10_12_1
  doi: 10.1111/j.1747-0285.2012.01325.x
– ident: e_1_2_10_10_1
  doi: 10.1016/j.molmet.2017.03.009
– ident: e_1_2_10_32_1
  doi: 10.2337/db10-0193
– ident: e_1_2_10_23_1
  doi: 10.2337/db19-235-LB
– ident: e_1_2_10_7_1
  doi: 10.1016/j.celrep.2017.09.065
– ident: e_1_2_10_47_1
  doi: 10.33549/physiolres.932099
– ident: e_1_2_10_57_1
  doi: 10.1016/j.bbrc.2012.07.165
– ident: e_1_2_10_26_1
  doi: 10.1183/13993003.00973-2018
– ident: e_1_2_10_33_1
  doi: 10.1210/en.2011-1496
– ident: e_1_2_10_17_1
  doi: 10.1016/j.cmet.2017.03.005
– ident: e_1_2_10_54_1
  doi: 10.1530/EC-16-0103
SSID ssj0036139
Score 2.3805902
Snippet Fibroblast growth factor 21 (FGF21) affects the regulation of metabolism. Additionally, anti‐inflammatory properties are attributed to FGF21, and studies in...
Fibroblast growth factor 21 (FGF21) affects the regulation of metabolism. Additionally, anti-inflammatory properties are attributed to FGF21, and studies in...
SourceID unpaywall
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 5998
SubjectTerms Adenosine
Apoptosis
Blood pressure
Body fat
Creatinine
Cross-Over Studies
Cytokines
Deoxyribonucleic acid
DNA
Electrocardiography
fibroblast growth factor 21
Fibroblast growth factors
Fibroblast Growth Factors - metabolism
Fibroblasts
Glucose
Growth factors
Healthy Volunteers
human endotoxin model
Humans
Hyperglycemia
Inflammation
lipopolysaccharide
Lipopolysaccharides
Lipopolysaccharides - pharmacology
Liver
Male
Metabolism
Original
Oxidative stress
Peptides
Prospective Studies
Protein expression
Proteins
Statistical analysis
Variance analysis
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NatwwEBZpSmkvpf91m5YpDYUWHGxJlqxDKSE0DYHtqQu5GcmWmwWvd7PZpfUtj1Dopc-XJ-lI_gGTsCcba7Atz8jzDZqZj5D9MlI5kyoKqRQ85NpEoRYqCVOXCCWiQqbMFQpPvouTKT89S852SJ_E3n3Ay1tDO8cnNV1VB78vmi-44D8PWTn5fH4QYzzOPywvQkco5TZeO3aNO-QuOi3lWB0mfNhgYOjFVNetdHyLsX-6ATpv5k7e39RL3fzSVTXGt95BHT8iDztkCYetKTwmO7Z-Qu61XJPNU_LvW5ucDrouoJotHTlCc6lzV3Y1Kyz0TCm44quqgVXLUW-hxHh6YRBjr-Enhuzrc2gpeoDGMKuhraNsYI6OBjzhH7gfHqoLcSVcX_2FQ8Dp9QWd4Gd9ffXHZY6Cpwx5RqbHX38cnYQdLUOYYyzHQ5sIo5VJI2ukFBHnTOgcDwY9HVMWIZEpdEG1FXnJTEGlQwkm0cYYncS2YM_Jbr2o7UsC-D_Gq1LRVAuuyzKNhBY0LpWNqSl4HpCPvTKyvOtZ7qgzqmyIXVBxmVdcQN4Pssu2U8etUnu9TrPe2DLquwCiXxYBeTcM4zpzmye6touNk2EKwRZLZUBetCYwPIYJ7nBhHBA5Mo5BwPXwHo_Us3Pfy9vVNXOG99wfzGjr23_yFrZFJDs9mkz82avtU31NHlBXyuFTc_bI7nq1sW8QYK3NW79U_gMFrCyn
  priority: 102
  providerName: Scholars Portal
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtNAEB5BKgQX_n8MBS2iF5AcbO96bR-jilJVSsWBSOVk7drrNsJxotRRZU59BCRO3HgWHqVPwuyubWGKKiROseKJ7d3MznybzHwfwE7hJRmNEs8NIs5cJqTnCp6EbqwLobiXRzHVjcLTQ74_YwdH4dFvXfyWH6L_wU2vDBOv9QJf5YWN82_7epxssRj7uBNn12GLh4jGR7A1O_ww-WRoUhE8osfG3TFLKGsZSocfHuakS0Dzcr3kzU21Es2ZKMshpjVJae8OiG44thbl83hTy3H25Q-mx_8Z71243SJWMrEudg-uqeo-3LAals0D-P7eFr0TUeWknK-06EJzKjLdzjXPFekUWDCSlGVD1upYC4YpUuDDLCVi95ocr5dn9Qmx0j8k8Mm8IrY_syELTGDECAkSHUjRDRCvkovzb2Ty8weOu-sUJWZqL86_6pJUYrRIHsJs793H3X231XtwM9wkMleFXIpExp6SUcQ9xigXGb5ITKE0UYi1ZC7yQCieFVTmQaThhwyFlFKEvsrpIxhVy0o9AYKBHt-NkiAWnImiiD0ueOAXifIDmbPMgdfdN55mLRm61uQo035ThFOdmql24FVvu7IUIH-12u4cJ23DwGkaGHpBTPjcgZf9aVzA-l8ZUanlRtvQBFEcjSMHHls_629DOdOA03cgGnhgb6DJwYdnqvmJIQnXDdOM4jV3el-98unfGN-7wiQ92J1OzdHTf7vmM7gV6F4RU_uzDaN6vVHPEcHV8kW7SH8B-0xL4Q
  priority: 102
  providerName: Unpaywall
– databaseName: Wiley Online Library Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NatwwEBZpSmkvpf91m5YpzaUFF1uSJQt6CaFpCGzpoYHcjGTLzYLXu2R3Kb7lEQI59dZn6aPkSTqSbNMlJdCTjT3-nRnNJ3tmPkJ260SVTKokplLwmGuTxFqoLM5dIpRIKpkzVyg8-SIOj_nRSXayRT4OtTChP8T4wc15hh-vnYNrs_zbycvZ7EOKs3B-i9xOEcg4-6b86zAOMwxUyndLRQyJhpv3zUl9Hs947GY4uoYxr6dK3l23C9390E2zCWd9PDp4QO73QBL2guYfki3bPiJ3ArVk95j8_Bxy0UG3FTTTheNC6Ja6dFVW08rCQIyCDt40HZwFSnoLNb6TuUFIvYLvOENfnUJg5AGawrSFUDbZwQzjCnh-P3DjG2oHYSRcnV_C3u9f-HxDASf4x746v3CZouApQp6Q44NP3_YP456GIS5x7sZjmwmjlckTa6QUCedM6BIXBiMbUxYhkKl0RbUVZc1MRaVDBSbTxhidpbZiT8l2O2_tcwI4_uJWqWiuBdd1nSdCC5rWyqbUVLyMyLtBG0XZ9yh3VBlNMc5VUHOF11xE3o6yi9CZ459SO4NSi947lwX1Xf8wDouIvBl3o1-5nyW6tfO1k2EKwRXLZUSeBRsYL8MEdzgwjYjcsI5RwPXs3tzTTk99725Xx8wZnnN3tKMb7_69N7EbRIqj_cnEr734H-GX5B51hRw-MWeHbK_O1vYVwquVee296A8H6SdB
  priority: 102
  providerName: Wiley-Blackwell
Title Glucose and lipopolysaccharide differentially regulate fibroblast growth factor 21 in healthy male human volunteers – A prospective cross‐over trial
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjcmm.17614
https://www.ncbi.nlm.nih.gov/pubmed/36415151
https://www.proquest.com/docview/2754439906
https://www.proquest.com/docview/2739431387
https://pubmed.ncbi.nlm.nih.gov/PMC9753437
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jcmm.17614
UnpaywallVersion publishedVersion
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1582-4934
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: KQ8
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1582-4934
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: KQ8
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1582-4934
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: KQ8
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals - NZ
  customDbUrl:
  eissn: 1582-4934
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: DOA
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1582-4934
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: DIK
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1582-4934
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: RPM
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVOVD
  databaseName: Journals@Ovid LWW All Open Access Journal Collection Rolling
  customDbUrl:
  eissn: 1582-4934
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: OVEED
  dateStart: 20000701
  isFulltext: true
  titleUrlDefault: http://ovidsp.ovid.com/
  providerName: Ovid
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1582-4934
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: BENPR
  dateStart: 20000701
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Health & Medical Complete
  customDbUrl:
  eissn: 1582-4934
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: 7X7
  dateStart: 20000701
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1582-4934
  dateEnd: 20250930
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: M48
  dateStart: 20000701
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVWIB
  databaseName: KBPluse Wiley Online Library: Open Access
  customDbUrl:
  eissn: 1582-4934
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: AVUZU
  dateStart: 20000701
  isFulltext: true
  titleUrlDefault: https://www.kbplus.ac.uk/kbplus7/publicExport/pkg/559
  providerName: Wiley-Blackwell
– providerCode: PRVWIB
  databaseName: Wiley Online Library Open Access
  customDbUrl:
  eissn: 1582-4934
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0036139
  issn: 1582-4934
  databaseCode: 24P
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fi9NAEB_uWkRfxP9Wz7LivSjESzab3eRBpB53HgctRYxUX8JusrGFNK13LdK3-wiCL36--yTObv5IOelLWpKh6TKzM79JZuYHcJi7UeqLyHWo4MxhUrmO5FHghKYQiruZCH3TKDwc8bOYnU-CyR6Mml4YU1bZ-ETrqLNFap6RH1E7qQ19J3-__OEY1ijzdrWh0JA1tUL2zo4Y24cuNZOxOtD9cDIaf2p8s4_BK6qHlNp6nnQ-f-thJs-2w9INrHmzZPL2ulzKzU9ZFNuw1sal03twtwaUZFBZwH3Y0-UDuFVRTG4ewp-PVU06kWVGitnScCJsLnEhU0ySM00aghTc6EWxIRcVNb0mOabRC4XQekW-Y6a-mpKKmYdQj8xKUrVPbsgc4wuxPH_E-DnUEsJJcn31mwwILq_p4yR21ddXv0zBKLFMIY8gPj35fHzm1GwMToopHHN0wJWMVOhqJQR3URlcpvihMMD5kUYkpDKZUal5mvsqo8KAAxVIpZQMPJ35j6FTLkr9FAi6YTwrIhpKzmSehy6XnHp5pD2qMpb24HWjjCStR5UbxowiaVMWVFxiFdeDV63sshrQ8V-pg0anSb1JL5N_JtWDl-1l3F7mnYks9WJtZPwIMZYfih48qUygvY3PmYGDXg_ElnG0AmZ09_aVcja1I7xNOzPz8TcPWzPa-e_fWAvbIZKcHw-H9tuz3Ut9Dneo6eCwFTkH0FldrPULxFUr1Yd9ysZ4FBPRh-7gS_wt7tcbqG-fVeBxyEI8F4_Gg69_ASkpMIE
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKK1QuiDcLBQZRDiAFEtvrJIcKldKyfewKoVbqLbUTp7tSNrvsQ6vc-hOQuPBr-DH9JYydB1oV9dZTomRkx5nxPJKZ-QjZTN0wZn7oOtQX3OFSuY4UYdsJTCKUcBM_YKZQuNsTnRN-cNo-XSF_6loYk1ZZ60SrqJNRbL6Rf6S2UxvqTvFp_MMxqFHm72oNoSEraIVky7YYqwo7DnWxwBBuurX_Bfn9ltK93eOdjlOhDDgxhibc0W2hZKgCVyvfFy5OImSMB4WKm4UaLbxKZEKlFnHKVEJ9Y_RUWyqlZNvTCcNxb5E1zniIwd_a593et--1LWBoLMOqKarNH4qHww-eLzy-bAav-LZXUzTX5_lYFguZZctutLWDe_fI3cqBhe1S4u6TFZ0_ILdLSMviIfn9tcyBB5knkA3GBoOhmOKL62NQnmioAVlQsWRZARN9bvDDNKQYto8UuvIzOJ-MFrM-lEhAQD0Y5FCWaxYwRHsGFlcQjF5FqUD3FS4vfsE24PLqulGwq768-GkSVMEikzwiJzfCl8dkNR_l-ikBVPt41Q9pIAWXaRq4QgrqpaH2qEp43CLvamZEcdUa3SB0ZFETIiHjIsu4FnnT0I7LhiD_pdqoeRpVSmEa_RPhFnnd3MbtbP7RyFyP5oaGhejTscBvkSelCDTTMMGN--m1iL8kHA2BaRW-fCcf9G3LcFM-zRmOudmI0bVP_95K2DUk0cFOt2vPnl2_1FdkvXPcPYqO9nuHz8kdaqpHbDbQBlmdTeb6Bfp0M_Wy2jhAzm56r_4FKiFnEg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIqAXxLuGAoMoB5BM7V1n1z4gVLWEPkjFgUq5mV173UZynJCHIt_6E5C48Fv4Of0lzK4fKCrKrSdH9sjOambnYX8zHyHbmRclTESeSwUP3EAqz5U86rihAUJxLxUhM43CvRN-cBoc9Tv9NfKn6YUxsMrGJ1pHnY4S8458h9pJbeg7-U5WwyK-7nc_jn-4hkHKfGlt6DQqEznW5QLLt-mHw33U9RtKu5--7R24NcOAm2BZEri6w5WMVOhpJQT38AFcJnhQ6LRZpDG6q1SmVGqeZEylVJiApzpSKSU7vk4Z3vcGuSkYiwycUPTbYo9hmIzqcagWOZQMh-99wf1gOQBeyWqvgjPvzIuxLBcyz5cTaBsBu_fI3Tp1hd3K1u6TNV08ILcqMsvyIfn9uUK_gyxSyAdjw75QTmVi-roGqYaGigVdSp6XMNFnhjlMQ4YF-0hhEj-Ds8loMTuHigMIqA-DAqpGzRKGGMnAMgqC8ahoD5i4wuXFL9gFXF7TMQp21ZcXPw00FSwnySNyei1aeUzWi1GhNwmgw8ezIqKh5IHMstDjklM_i7RPVRokDnnbKCNO6qHohpsjj9viCBUXW8U55HUrO65GgfxXaqvRaVy7g2n8z3gd8qq9jBvZfJ2RhR7NjQyLMJtjoXDIk8oE2scwHpjE03eIWDKOVsAMCV--UgzO7bBw0zgdMLzndmtGK__9O2thK0Tio71ez_56unqpL8lt3KHxl8OT42dkg5q2EQsD2iLrs8lcP8dkbqZe2F0D5Pt1b9O_fMFkrA
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtNAEB5BKgQX_n8MBS2iF5AcbO96bR-jilJVSsWBSOVk7drrNsJxotRRZU59BCRO3HgWHqVPwuyubWGKKiROseKJ7d3MznybzHwfwE7hJRmNEs8NIs5cJqTnCp6EbqwLobiXRzHVjcLTQ74_YwdH4dFvXfyWH6L_wU2vDBOv9QJf5YWN82_7epxssRj7uBNn12GLh4jGR7A1O_ww-WRoUhE8osfG3TFLKGsZSocfHuakS0Dzcr3kzU21Es2ZKMshpjVJae8OiG44thbl83hTy3H25Q-mx_8Z71243SJWMrEudg-uqeo-3LAals0D-P7eFr0TUeWknK-06EJzKjLdzjXPFekUWDCSlGVD1upYC4YpUuDDLCVi95ocr5dn9Qmx0j8k8Mm8IrY_syELTGDECAkSHUjRDRCvkovzb2Ty8weOu-sUJWZqL86_6pJUYrRIHsJs793H3X231XtwM9wkMleFXIpExp6SUcQ9xigXGb5ITKE0UYi1ZC7yQCieFVTmQaThhwyFlFKEvsrpIxhVy0o9AYKBHt-NkiAWnImiiD0ueOAXifIDmbPMgdfdN55mLRm61uQo035ThFOdmql24FVvu7IUIH-12u4cJ23DwGkaGHpBTPjcgZf9aVzA-l8ZUanlRtvQBFEcjSMHHls_629DOdOA03cgGnhgb6DJwYdnqvmJIQnXDdOM4jV3el-98unfGN-7wiQ92J1OzdHTf7vmM7gV6F4RU_uzDaN6vVHPEcHV8kW7SH8B-0xL4Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Glucose+and+lipopolysaccharide+differentially+regulate+fibroblast+growth+factor+21+in+healthy+male+human+volunteers+%E2%80%93+A+prospective+cross%E2%80%90over+trial&rft.jtitle=Journal+of+cellular+and+molecular+medicine&rft.au=Pohlhammer%2C+Johannes&rft.au=Heinzl%2C+Matthias+Wolfgang&rft.au=Klammer%2C+Carmen&rft.au=Feldbauer%2C+Roland&rft.date=2022-12-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.eissn=1582-4934&rft.volume=26&rft.issue=24&rft.spage=5998&rft.epage=6005&rft_id=info:doi/10.1111%2Fjcmm.17614&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1582-1838&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1582-1838&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1582-1838&client=summon